Kazia Therapeutics (KZIA) Payables (2017 - 2025)

Kazia Therapeutics' Payables history spans 6 years, with the latest figure at $6.7 million for Q2 2025.

  • For Q2 2025, Payables fell 34.93% year-over-year to $6.7 million; the TTM value through Jun 2025 reached $6.7 million, down 34.93%, while the annual FY2025 figure was $6.7 million, 34.93% down from the prior year.
  • Payables reached $6.7 million in Q2 2025 per KZIA's latest filing, down from $10.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $10.3 million in Q2 2024 to a low of $1.4 million in Q2 2022.
  • Average Payables over 4 years is $5.6 million, with a median of $5.4 million recorded in 2023.
  • Peak YoY movement for Payables: surged 197.98% in 2023, then tumbled 34.93% in 2025.
  • A 4-year view of Payables shows it stood at $1.4 million in 2022, then soared by 197.98% to $4.1 million in 2023, then soared by 152.76% to $10.3 million in 2024, then tumbled by 34.93% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for KZIA's Payables are $6.7 million (Q2 2025), $10.3 million (Q2 2024), and $4.1 million (Q2 2023).